Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibition of TRPC6 degradation suppresses ischemic brain damage in rats
Wanlu Du, … , Bo Duan, Yizheng Wang
Wanlu Du, … , Bo Duan, Yizheng Wang
Published September 1, 2010
Citation Information: J Clin Invest. 2010;120(10):3480-3492. https://doi.org/10.1172/JCI43165.
View: Text | PDF
Research Article Neuroscience

Inhibition of TRPC6 degradation suppresses ischemic brain damage in rats

  • Text
  • PDF
Abstract

Brain injury after focal cerebral ischemia, the most common cause of stroke, develops from a series of pathological processes, including excitotoxicity, inflammation, and apoptosis. While NMDA receptors have been implicated in excitotoxicity, attempts to prevent ischemic brain damage by blocking NMDA receptors have been disappointing. Disruption of neuroprotective pathways may be another avenue responsible for ischemic damage, and thus preservation of neuronal survival may be important for prevention of ischemic brain injury. Here, we report that suppression of proteolytic degradation of transient receptor potential canonical 6 (TRPC6) prevented ischemic neuronal cell death in a rat model of stroke. The TRPC6 protein level in neurons was greatly reduced in ischemia via NMDA receptor–dependent calpain proteolysis of the N-terminal domain of TRPC6 at Lys16. This downregulation was specific for TRPC6 and preceded neuronal death. In a rat model of ischemia, activating TRPC6 prevented neuronal death, while blocking TRPC6 increased sensitivity to ischemia. A fusion peptide derived from the calpain cleavage site in TRPC6 inhibited degradation of TRPC6, reduced infarct size, and improved behavioral performance measures via the cAMP response element–binding protein (CREB) signaling pathway. Thus, TRPC6 proteolysis contributed to ischemic neuronal cell death, and suppression of its degradation preserved neuronal survival and prevented ischemic brain damage.

Authors

Wanlu Du, Junbo Huang, Hailan Yao, Kechun Zhou, Bo Duan, Yizheng Wang

×

Figure 1

TRPC6 in the neurons was downregulated in ischemia.

Options: View larger image (or click on image) Download as PowerPoint
TRPC6 in the neurons was downregulated in ischemia.
(A) Immunoblots of t...
(A) Immunoblots of the extracts from the contralateral (C) or ipsilateral (I) cortex (sham; left [L] or right [R] hemisphere) using the indicated antibodies. Tubulin served as a loading control. Right panel: quantification of the normalized TRPC6 protein levels (n = 5–8 rats per time point). *P < 0.05; **P < 0.01 versus sham. (B) Immunoblots for TRPCs and GluR1 after 24 hours reperfusion (R24). Right panel: quantification of the protein levels (n = 5 rats). **P < 0.01 versus contralateral. (C) TRPC6 mRNA levels determined by qRT-PCR (n = 3–5 rats per time point). (D) Representative images of the indicated cortex after 24 hours reperfusion (R24) double-stained with the indicated antibodies. Scale bar: 50 μm. Quantification of the optical density for both TRPC6 and NeuN immunoreactivity is shown on the right panel (n = 5 rats). **P < 0.01 versus the density in contralateral cortex. Data are presented as mean ± SEM. Unless stated, TRPC6 antibody from Millipore was used for Figures 1, 2, and 6 and antibody from Alomone Labs was used for Figures 3, 4, 5, and 7.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts